Fax: (212) 746-3844
Final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma
Version of Record online: 13 OCT 2008
Copyright © 2008 American Cancer Society
Volume 113, Issue 10, pages 2714–2723, 15 November 2008
How to Cite
Leonard, J. P., Schuster, S. J., Emmanouilides, C., Couture, F., Teoh, N., Wegener, W. A., Coleman, M. and Goldenberg, D. M. (2008), Durable complete responses from therapy with combined epratuzumab and rituximab . Cancer, 113: 2714–2723. doi: 10.1002/cncr.23890
Presented in abstract form at the 49th Annual Meeting of the American Society of Hematology, Atlanta, Georgia, December 8-11, 2007.
J.P.L., W.A.W., and D.M.G. were responsible for study design; Immunomedics, Inc. (W.A.W.) provided epratuzumab; J.P.L., S.J.S., C.E., F.C., and M.C. provided patients; W.A.W. and N.T. collected and assembled data; J.P.L., W.A.W., and N.T. provided data analysis; J.P.L., W.A.W., M.C., and D.M.G. interpreted the data; J.P.L., W.A.W., N.T., and D.M.G. wrote the article; and all authors reviewed and approved the article.
- Issue online: 3 NOV 2008
- Version of Record online: 13 OCT 2008
- Manuscript Accepted: 24 JUN 2008
- Manuscript Revised: 22 JUN 2008
- Manuscript Received: 8 MAY 2008
- Amgen Inc. (Thousand Oaks, Calif) in a collaboration with Immunomedics, Inc. (Morris Plains, NJ)
- durable response;
- follicular lymphoma;
- Follicular Lymphoma International Prognostic Index;
- small lymphocytic lymphoma
In this international, multicenter trial, the authors evaluated rituximab (anti-CD20) plus epratuzumab (anti-CD22) in patients with postchemotherapy relapsed/refractory, indolent non-Hodgkin lymphoma (NHL), including long-term efficacy.
Forty-nine patients with follicular NHL (FL) (N = 41) or small lymphocytic lymphoma (SLL) (N = 7) received intravenous epratuzumab 360 mg/m2 and then intravenous rituximab 375 mg/m2 weekly ×4. The regimen was tolerated well.
Twenty-two of 41 patients with FL (54%) had an objective response (OR), including 10 (24%) complete responses (CR) (CR/unconfirmed CR [CRu]), whereas 4 of 7 patients with SLL (57%) had ORs, including 3 (43%) with CR/CRu. Rituximab-naive patients (N = 34) had an OR rate of 50% (26% CR/CRu rate), whereas patients who previously responded to rituximab (N = 14) had an OR rate of 64% (29% CR/CRu rate). An OR rate of 85% was observed in patients with FL who had Follicular Lymphoma International Prognostic Index (FLIPI) risk scores of 0 or 1 (N = 13), whereas 28 patients with intermediate or high-risk FLIPI scores (≥2) had an OR rate of 39% (18% CR/CRu rate). In patients with FL, the median response duration was 13.4 months, and that duration increased to 29.1 months for 10 patients who had a CR/CRu, including 4 patients who had durable responses with remissions that continued for >4 years. In patients with SLL, the median response duration was 20 months, including 1 patient who had a response that continued for >3 years.
The combination of epratuzumab and rituximab induced durable responses in patients with recurrent, indolent NHL. Cancer 2008. © 2008 American Cancer Society.